Month: April 2022

Apr 27 2022

Uncategorized

Health Canada Approves AbbVie Treatment for Bipolar Disorder, Schizophrenia

by Clinical Editor

No Comments

By Adriano Marchese AbbVie Inc. said Wednesday that Health Canada has approved its treatment for symptoms associated with bipolar disorder and …

Apr 26 2022

Uncategorized

Schizophrenia Identified as Second Biggest Risk Factor for Death from COVID – Health News Hub

by Clinical Editor

No Comments

Schizophrenia Identified as Second Biggest Risk Factor for Death from COVID  Health News Hub New genetic link to schizophrenia identified  The Washington Post Schizophrenia: Gene discovery indicates risk and cause  DW (English) Scientists...

Apr 26 2022

Uncategorized

Schizophrenia and the Family: Getting the Diagnosis – Psychology Today

by Clinical Editor

No Comments

Schizophrenia and the Family: Getting the Diagnosis  Psychology Today

Apr 26 2022

Uncategorized

FDA approves new dosage strengths for bipolar, schizophrenia drug – Healio

by Clinical Editor

No Comments

FDA approves new dosage strengths for bipolar, schizophrenia drug  Healio

Apr 26 2022

Uncategorized

Schizophrenia: The Recovery Process

by Clinical Editor

No Comments

Recovery from schizophrenia can be a slow process. However, it is important to never give up and always strive for wellness and a better life. I have been in full...

Apr 26 2022

Uncategorized

Reviva Pharmaceuticals to Host Key Opinion Leader Webinar on Brilaroxazine for Schizophrenia and Other Neuropsychiatric Disorders

by Clinical Editor

No Comments

AM ET An overview of unmet medical needs and therapeutic opportunities in schizophrenia and major neuropsychiatric disorders will be discussed CUPERTINO, Calif., April 26, …

Apr 26 2022

Uncategorized

Global Schizophrenia Drugs Market Research Report 2022-2027 – Injectable-Based Treatment of Schizophrenia Exhibits a Significant Growth

by Clinical Editor

No Comments

The “Global Schizophrenia Drugs Market, Size, Forecast 2022-2027, Industry Trends, Share, Growth, Insight, Impact of COVID-19, Company Analysis” report has been added to ResearchAndMarkets.com’s …

Apr 26 2022

Uncategorized

FDA approves new dosage strengths for bipolar, schizophrenia drug

by Clinical Editor

No Comments

The FDA has granted approval to Intra-Cellular Therapies Inc. for 10.5 mg and 21 mg dosages of lumateperone to treat schizophrenia and bipolar depression, according to a company release.Lumateperone …

Apr 26 2022

Uncategorized

Zandile Mafe made ‘confession’ after paranoid schizophrenia diagnosis, court hears

by Clinical Editor

No Comments

Dali Mpofu told the Western Cape High Court that Zandile Mafe’s alleged confession was worthless as it was made hours after he was assessed.

Apr 25 2022

Uncategorized

Schizophrenia: The Recovery Process

by Clinical Editor

No Comments

Recovery from schizophrenia can be a slow process. However, it is important to never give up and always strive for wellness and a better life. I have been in full...